Abstract Details

Title Real-World Clinical Utilization Differences of onabotulinumtoxinA and abobotulinumtoxinA in Upper Limb Spasticity

Topic Neuro-rehabilitation

Presentation(s) P12 - Poster Session 12 (5:30 PM-6:30 PM)

Poster/Presentation
Number 10-013

Objective To compare real-world clinical utilization of onabotulinumtoxinA (onabotA) and abobotulinumtoxinA (abobotA) in the treatment of adult upper limb spasticity (ULS).

Background 3 botulinum toxin type A (BoNT/A) products are approved by the US Food and Drug Administration (FDA) to treat ULS. Each BoNT/A product is manufactured and tested via proprietary processes, resulting in unique clinical profiles. FDA-mandated boxed warnings state that potency units of one product are not interchangeable and cannot be converted into units of another BoNT/A product. We compared real-world clinical utilization of onabotA and abobotA in the treatment of adult ULS.

Design/Methods De-identified medical records were obtained via survey of 101 unique healthcare professionals on patients diagnosed with ULS per International Classification of Diseases, 10th revision, (ICD-10) and treated via botulinum toxin using current procedural terminology (CPT) in the US. 215 patient charts were reviewed: 107 treated with onabotA and 108 with abobotA. Patients received at least 3 treatments of onabotA or abobotA in 1 spastic upper limb prior to March 2020. Number and type of muscles injected were compared between BoNT/A products.

Results 75% of patients were classified as having moderate-to-severe ULS by the injector. On average, patients were diagnosed with ULS for >3 years: onabotA 44.2 months (10-200) or abobotA 40.0 months (11-212). A significantly greater average number of muscles were injected with onabotA (4.3; range, 1 to 16), compared with abobotA (3.1; range, 1 to 8), P=0.0001. Significantly more patients received onabotA injections in forearm muscles (87/107, 81.3%) compared with abobotA (70/108, 64.8%), P=0.0064. Similarly, a significant difference was observed in the utilization of onabotA in hand muscles (23/107, 21.5%) compared with abobotA (4/108, 3.7%), P=0.0001.

Conclusions These results are consistent with published evidence across other indications, further supporting that each BoNT/A product is unique and not interchangeable as indicated by the FDA.

Authors/Disclosures
Rita Singh, PharmD (Allergan) PRESENTER	Dr. Singh has received personal compensation for serving as an employee of AbbVie. Dr. Singh has stock in AbbVie.
Mariana Nelson, PhD (AbbVie/Allergan US Medical Affairs)	Dr. Nelson has received personal compensation for serving as an employee of AbbVie. Dr. Nelson has stock in AbbVie Inc.
Aleksej Zuzek, PhD (Allergan)	Dr. Zuzek has received personal compensation for serving as an employee of AbbVie Inc.. Dr. Zuzek has stock in AbbVie Inc..
	No disclosure on file

��ɫ��

��ɫ��